Is Echo IQ (ASX:EIQ) a Buy? Mayo Clinic Deal and ASX Index Entry Signal a Major Turning Point

Echo IQ (ASX:EIQ) is surging today on the back of two catalysts arriving at once. The company has secured a distribution partnership with the Mayo Clinic across a 30-hospital network, and the stock has been added to the ASX All Ordinaries Index. Despite these milestones, the share price remains well under A$0.30, which raises the key question for investors right now: is this the moment to buy, or should you wait for FDA clearance before committing?

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

What the Mayo Clinic Deal Actually Means

This is not simply a validation stamp from a famous institution. The Mayo Clinic partnership gives Echo IQ active distribution rights across one of the most respected hospital networks in the world. In a clinical study conducted at Mayo across more than 17,000 echocardiograms, the company’s EchoSolv HF software detected heart failure with 99.5% sensitivity. That result is what earned the commercial relationship, not just a research footnote.
Following that study, Echo IQ lodged its FDA 510(k) submission for EchoSolv HF. Clearance is now the single biggest commercial trigger on the horizon. For investors, the Mayo deal is significant because it removes a critical question about market access. The distribution channel into 30 hospitals is already in place. Once FDA clearance arrives, the company does not need to build that network from scratch.

Buy Now or Wait for FDA? The Investor’s Takeaway

The bull case rests on three things coming together. The Mayo deal de-risks commercialisation. Index inclusion brings a new wave of institutional buyers. And FDA clearance for EchoSolv HF is the re-rating event that could shift the stock significantly higher.
The bear case is straightforward. Echo IQ is pre-revenue on its main product. FDA timelines are uncertain, and healthcare adoption in the US tends to move slowly even after clearance.
It is worth noting that Pro Medicus (ASX:PME) signed its own Mayo Clinic agreement in 2016 and never looked back. We are not suggesting EIQ is the next Pro Medicus, but the parallel is worth keeping in mind when thinking about what institutional hospital partnerships can mean for Australian healthtech companies.
We believe Echo IQ represents a speculative buy for risk-tolerant investors at current levels. The FDA clearance decision is the real re-rating trigger, but investors waiting for confirmed clearance may find the move has already happened by then.